“A principio fuit canonicus”: The Controversy over 1 Enoch in Seventeenth-Century Europe
Harvard Theological Review · 2026-01 · 119 (1) · 143-167
DOI: 10.1017/s0017816026101126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Harvard Theological Review, online erschienen am 30.03.2026. Verfasst von Kirsten Macfarlane. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The past decade has seen significant advances in our understanding of the early modern reception of 1 Enoch, thanks to the pioneering work of Ariel Hessayon, Annette Yoshiko Reed, and Gabriele Boccaccini among others. Building on their research, this article reconstructs the dynamics that generated interest in 1 Enoch in early modernity, focussing on the reception of the Syncellus fragments published in 1606 by Joseph Scaliger. To do so, it offers three observations. Firstly, it expands our understanding of the nature of interest in 1 Enoch prior to 1606. Secondly, it corrects a common misinterpretation of Scaliger’s comments on the Syncellus fragments. Finally, it reconstructs three trends which arose after Scaliger and which functioned to perpetuate interest in 1 Enoch. This account should interest both scholars of Enoch’s afterlives and historians of scholarship for the light it sheds on the development of early modern biblical criticism.
Zitieren
APA
Macfarlane, K. (2026). “A principio fuit canonicus”: The Controversy over 1 Enoch in Seventeenth-Century Europe. Harvard Theological Review, 119(1), 143-167. https://doi.org/10.1017/s0017816026101126
Vancouver
Macfarlane K. “A principio fuit canonicus”: The Controversy over 1 Enoch in Seventeenth-Century Europe. Harvard Theological Review. 2026;119(1):143-167. doi:10.1017/s0017816026101126
BibTeX
@article{Macfarlane2026,
author = {Macfarlane, Kirsten},
title = {“A principio fuit canonicus”: The Controversy over 1 Enoch in Seventeenth-Century Europe},
journal = {Harvard Theological Review},
year = {2026},
volume = {119},
number = {1},
pages = {143--167},
doi = {10.1017/s0017816026101126}
}
EUVIMED